Status:
COMPLETED
Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy
Lead Sponsor:
Mansoura University
Conditions:
Contrast-induced Nephropathy
Statin
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To evaluate the benefit for statin use in prevention of of CI-AKI after computed tomography urogram (CTU).
Eligibility Criteria
Inclusion
- Planned computed tomography urogram (CTU)
- Statin naive, or not on statin treatment for at least 14 day
Exclusion
- History of liver disease or elevated serum transaminases
- History of rhabdomyolysis or elevated creatinine kinase
- History of iodinated CM use within 14 days before randomization
- History of N-acetylcysteine, metformin or nonsteroidal anti-inflammatory drugs use within 48 hours of the procedure.
- History of hypersensitivity reaction to contrast media
- Pregnancy or lactation
- Acute renal failure
- End-stage renal disease requiring dialysis
- Cardiogenic shock or pulmonary edema
- Multiple myeloma
Key Trial Info
Start Date :
January 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT03391830
Start Date
January 15 2018
End Date
January 1 2020
Last Update
January 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology and Nephrology Center
Al Mansurah, Aldakahlia, Egypt, 35516